相似文献
1
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.一种单克隆抗体对奥密克戎亚变体表现突出：呼吁采取行动以更广泛获取贝博泰洛维单抗。
Lancet Infect Dis. 2022 Sep;22(9):1278. doi: 10.1016/S1473-3099(22)00495-9. Epub 2022 Jul 18.
2
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.贝特洛维单抗和索特罗维单抗治疗奥密克戎纪元中 COVID-19 轻症至中症的实体器官移植受者的结局。
Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.
3
Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants.关于用于中和奥密克戎亚变体的贝博洛维单抗（LY-CoV1404）的担忧。
J Med Virol. 2023 Feb;95(2):e28565. doi: 10.1002/jmv.28565.
4
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体对治疗性单克隆抗体的中和敏感性
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
5
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.贝博洛维单抗和索托维单抗治疗奥密克戎流行期间2019冠状病毒病高危人群的真实世界临床结局
Open Forum Infect Dis. 2022 Oct 6;9(10):ofac411. doi: 10.1093/ofid/ofac411. eCollection 2022 Oct.
6
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.奥密克戎突变增强了 SARS-CoV-2 病毒样颗粒的感染力，并降低了抗体的中和作用。
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119. doi: 10.1073/pnas.2200592119. Epub 2022 Jul 19.
7
Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.第三剂 mRNA 疫苗接种后对 SARS-CoV-2 奥密克戎 BA.1、BA.2 和 BA.3 的抗体亲和力和跨变体中和作用。
Nat Commun. 2022 Aug 8;13(1):4617. doi: 10.1038/s41467-022-32298-w.
8
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.奥密克戎 BA.1 和 BA.2 变异株对疫苗诱导的血清和治疗性单克隆抗体的耐药性。
Viruses. 2022 Jun 18;14(6):1334. doi: 10.3390/v14061334.
9
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
10
Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.目前可用的针对 SARS-CoV-2 的人源中和抗体图谱以及奥密克戎亚变体 BA.1/BA.1.1/BA.2/BA.3 的逃逸
Immunity. 2022 Aug 9;55(8):1501-1514.e3. doi: 10.1016/j.immuni.2022.06.005. Epub 2022 Jun 15.
引用本文的文献
1
High Quality-Factor All-Dielectric Metacavity for Label-Free Biosensing.用于无标记生物传感的高品质因数全介质超腔
Adv Sci (Weinh). 2025 Jan;12(4):e2410125. doi: 10.1002/advs.202410125. Epub 2024 Nov 18.
2
The influence of Omicron on vaccine efficacy and durability: a neurology perspective.奥密克戎对疫苗效力和持久性的影响：神经学视角
Clin Exp Vaccine Res. 2024 Jul;13(3):175-183. doi: 10.7774/cevr.2024.13.3.175. Epub 2024 Jul 31.
3
A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants.一种VHH单域平台，可用于发现和开发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的单特异性抗体和模块化中和双特异性抗体。
Antib Ther. 2024 May 3;7(2):164-176. doi: 10.1093/abt/tbae009. eCollection 2024 Apr.
4
Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning.通过微量样本驱动生物传感器和机器学习对 SARS-CoV-2 加强灭活疫苗抗体反应进行动态分析和预测
Vaccines (Basel). 2024 Mar 25;12(4):352. doi: 10.3390/vaccines12040352.
5
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.利用免疫脂质体作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其新出现变体的纳米载体。
Asian J Pharm Sci. 2023 Nov;18(6):100855. doi: 10.1016/j.ajps.2023.100855. Epub 2023 Oct 20.
6
Healing Treatments in COVID-19 Patients: A Narrative Review.新冠病毒肺炎患者的治疗方法：一项叙述性综述
J Clin Med. 2023 Jul 14;12(14):4672. doi: 10.3390/jcm12144672.
7
Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.α-1-抗胰蛋白酶拮抗 COVID-19：流行病学、分子机制和临床证据综述。
Biochem Soc Trans. 2023 Jun 28;51(3):1361-1375. doi: 10.1042/BST20230078.
8
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.卡西瑞维单抗与英夫维单抗抗体组合在免疫功能低下的2019冠状病毒病住院患者中的有效性：一项1/2/3期双盲试验的事后分析
Open Forum Infect Dis. 2023 Apr 19;10(5):ofad211. doi: 10.1093/ofid/ofad211. eCollection 2023 May.
9
Treating COVID-19: Targeting the Host Response, Not the Virus.治疗新冠病毒病：针对宿主反应，而非病毒。
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
10
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.植物作为生产治疗性蛋白质和抗病毒化合物以对抗新冠病毒的生物工厂。
Life (Basel). 2023 Feb 23;13(3):617. doi: 10.3390/life13030617.
本文引用的文献
1
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
2
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体对治疗性单克隆抗体的中和敏感性
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
Zotero 插件